Saphnelo (anifrolumab) is a prescription medication used to treat moderate to severe systemic lupus erythematosus (SLE), commonly known as lupus. It is given as an intravenous infusion every four weeks and works by targeting a specific part of the immune system that drives lupus activity in the majority of patients. The FDA approved it in 2021 for adults who are already receiving standard lupus therapy but still have active disease.
How Saphnelo Works
Lupus is an autoimmune disease in which the immune system mistakenly attacks healthy tissue, causing inflammation in the joints, skin, kidneys, and other organs. A group of immune signaling proteins called type I interferons plays a central role in this process. Roughly 60 to 80 percent of adults with active lupus have abnormally high levels of genes activated by these interferons, which essentially keep the immune system in overdrive.
Saphnelo is a monoclonal antibody that locks onto the receptor cells use to receive type I interferon signals. By blocking that receptor, it shuts down the chain of inflammatory events that interferons would normally trigger. It also pulls the receptor itself off the cell surface, further reducing the cell’s ability to respond to interferon signaling. The downstream effects include calming overactive immune cells and reducing the production of antibodies that attack the body’s own tissues.
What Treatment Looks Like
Saphnelo is delivered through an IV infusion at a clinic or infusion center, typically once every four weeks. Each session takes about 30 minutes for the infusion itself, though you should expect to spend additional time on check-in and a short observation period afterward. It is not a standalone treatment. You continue taking your existing lupus medications, and Saphnelo is added on top of them.
One of the goals of adding Saphnelo is to help reduce dependence on corticosteroids like prednisone, which many lupus patients take long-term despite significant side effects. In clinical trials, about 56 percent of patients on Saphnelo achieved a sustained reduction in their steroid dose (to 7.5 mg per day or less), compared with roughly 33 percent on placebo. That difference matters, because long-term steroid use contributes to bone loss, weight gain, diabetes, and other complications.
Who Saphnelo Is For
Saphnelo is approved for adults with moderate to severe lupus who are already on standard therapy but still experiencing active symptoms such as joint pain, skin rashes, or fatigue. It was not studied in patients with severe lupus nephritis (kidney inflammation from lupus) or neuropsychiatric lupus (lupus affecting the brain and nervous system), so it is not currently recommended for those specific forms of the disease.
Because the drug works by blocking type I interferon signaling, patients with high interferon gene activity tend to benefit the most. Your rheumatologist may consider testing your interferon signature when deciding whether Saphnelo is a good fit for you.
Common Side Effects
Because Saphnelo dials down part of the immune system, infections are the most frequent concern. In clinical trials involving over 900 patients, upper respiratory infections (including colds and sore throats) occurred in 34 percent of patients on Saphnelo compared with 23 percent on placebo. Bronchitis was also more common, affecting 11 percent versus about 5 percent.
The side effects reported in at least 5 percent of patients include:
- Upper respiratory infections (34%)
- Bronchitis (11%)
- Infusion-related reactions (9.4%), most often headache, nausea, vomiting, fatigue, or dizziness
- Herpes zoster (shingles) (6.1%, compared with 1.3% on placebo)
- Cough (5%)
The shingles risk stands out. Patients on Saphnelo developed shingles at nearly five times the rate of those on placebo. If you haven’t been vaccinated against shingles, that’s a conversation worth having before starting treatment.
Serious Risks
Serious infections, including pneumonia and COVID-19, were the most notable severe events in longer-term follow-up studies. Because Saphnelo suppresses part of the immune response, any infection has the potential to become more severe than it otherwise would. Hypersensitivity reactions occurred in about 2.8 percent of patients, compared with 0.6 percent on placebo.
Infusion-related reactions were generally mild to moderate. They affected about 9 percent of patients and typically involved symptoms like headache, nausea, and dizziness during or shortly after the infusion. Severe infusion reactions were uncommon.
How Saphnelo Compares to Other Lupus Treatments
Before Saphnelo, the only biologic approved specifically for lupus was belimumab (Benlysta), which works by a completely different mechanism: blocking a protein that helps certain immune cells survive. Saphnelo targets the interferon pathway instead, making it a distinct option for patients who haven’t responded well to other treatments. The two drugs have not been directly compared in a head-to-head trial, so the choice between them depends on individual disease characteristics, prior treatment history, and how much interferon activity is driving symptoms.
For many lupus patients, standard therapy alone (antimalarials, immunosuppressants, steroids) controls the disease adequately. Saphnelo fills a gap for those whose lupus remains active despite these medications, offering a biologic option that addresses one of the most common underlying immune drivers of the disease.